Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates a new immunotherapy combination of REGN7075 and Libtayo (cemiplimab) targeting advanced solid tumors. This trial is among the first to show effectiveness in patients with microsatellite stable colorectal cancer (MSS CRC), a type traditionally resistant to immunotherapies. […]
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for advanced or recurrent cervical cancer. Libtayo is a type of immunotherapy intended for the treatment of patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy. The approval […]
Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), which is one of the most commonly diagnosed skin cancers. Libtayo, which is a fully-human monoclonal antibody targeting the immune checkpoint receptor programmed cell death […]
